- Home
- STEC vs PULM Comparison
STEC vs PULM Comparison
Compare STEC & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- PULM
- Stock Information
- Founded
- STEC 2006
- PULM 2003
- Country
- STEC Hong Kong
- PULM United States
- Employees
- STEC N/A
- PULM N/A
- Industry
- STEC
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- PULM Health Care
- Exchange
- STEC NYSE
- PULM Nasdaq
- Market Cap
- STEC 63.8M
- PULM 20.5M
- IPO Year
- STEC 2021
- PULM N/A
- Fundamental
- Price
- STEC $0.74
- PULM $5.57
- Analyst Decision
- STEC
- PULM
- Analyst Count
- STEC 0
- PULM 0
- Target Price
- STEC N/A
- PULM N/A
- AVG Volume (30 Days)
- STEC 10.9K
- PULM 10.9K
- Earning Date
- STEC 08-05-2025
- PULM 08-12-2025
- Dividend Yield
- STEC N/A
- PULM N/A
- EPS Growth
- STEC N/A
- PULM N/A
- EPS
- STEC N/A
- PULM N/A
- Revenue
- STEC $10,672,000.00
- PULM $1,921,000.00
- Revenue This Year
- STEC $9,392.20
- PULM N/A
- Revenue Next Year
- STEC N/A
- PULM $134.88
- P/E Ratio
- STEC N/A
- PULM N/A
- Revenue Growth
- STEC N/A
- PULM N/A
- 52 Week Low
- STEC $0.20
- PULM $1.78
- 52 Week High
- STEC $3.25
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- STEC 40.44
- PULM 36.25
- Support Level
- STEC $0.70
- PULM $5.20
- Resistance Level
- STEC $0.80
- PULM $6.15
- Average True Range (ATR)
- STEC 0.08
- PULM 0.30
- MACD
- STEC 0.00
- PULM -0.05
- Stochastic Oscillator
- STEC 38.55
- PULM 22.70
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. It has two revenue segments Wealth management service and Asset management service. Key revenue is generated from Wealth management service.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).